Page last updated: 2024-11-10

cinepazide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5282459
CHEMBL ID1874750
CHEBI ID135676
SCHEMBL ID34092
MeSH IDM0087903

Synonyms (50)

Synonym
NCGC00181123-01
piperazine, 1-(2-oxo-2-(1-pyrrolidinyl)ethyl)-4-(1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl)-
brn 0903854
cinepazida [inn-spanish]
piperazine, 1-((1-pyrrolidinylcarbonyl)methyl)-4-(3,4,5-trimethoxycinnamoyl)-
cinepazidum [inn-latin]
einecs 245-928-9
1-((1-pyrrolidinylcarbonyl)methyl)-4-(3,4,5-trimethoxycinnamoyl)piperazine
cinepazide [inn:ban:dcf]
cinepazide
CHEBI:135676
(e)-1-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
unii-67y4p5c84x
23887-46-9
cinepazidum
cinepazida
67y4p5c84x ,
md 67350 [as maleate]
md 67350 free base
CHEMBL1874750
md-67350 free base
2-propen-1-one,1-[4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]-3-(3,4,5-trimethoxyphenyl)-
HY-66010A
smr004701237
MLS006010093
SCHEMBL34092
cinepazide [who-dd]
cinepazide [mi]
cinepazide [inn]
AKOS025149472
AB01565811_02
1-(pyrrolidin-1-ylcarbonylmethyl)-4-(3,4,5-trimethoxycinnamoyl)piperazine
1-{4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperazin-1-yl}-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
J-015259
mfcd00868266
NCGC00181123-02
Z82971773
88197-48-2
(e)-1-(4-(2-oxo-2-(pyrrolidin-1-yl)ethyl)piperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
DB12123
Q5120864
AS-13346
NCGC00181123-04
A924165
1-[(1-pyrrolidinylcarbonyl)methyl]-4-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]piperazine
DTXSID901112229
cinepazide free base
23887-46-9 (free base)
2-propen-1-one, 1-[4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]-3-(3,4,5-trimethoxyphenyl)-, (2e)-
EN300-1212497

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Safety was evaluated by recording all adverse events (AEs), monitoring laboratory parameters and vital signs, and electrocardiogram."( Efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke: a multicenter, randomized, double-blind, placebo-controlled trial.
Cai, X; Chen, G; Chen, H; Cui, L; Ding, J; Geng, D; Gong, T; Huang, Y; Ji, Y; Li, X; Liu, Y; Lü, H; Ni, J; Qu, X; Shao, B; Wang, J; Wei, Y; Wu, J; Xiao, B; Yang, Y; Yi, F; Zhang, Z, 2020
)
0.87
" Cinepazide maleate injection was safe and well tolerated with no unexpected AEs reported."( Efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke: a multicenter, randomized, double-blind, placebo-controlled trial.
Cai, X; Chen, G; Chen, H; Cui, L; Ding, J; Geng, D; Gong, T; Huang, Y; Ji, Y; Li, X; Liu, Y; Lü, H; Ni, J; Qu, X; Shao, B; Wang, J; Wei, Y; Wu, J; Xiao, B; Yang, Y; Yi, F; Zhang, Z, 2020
)
1.78

Pharmacokinetics

ExcerptReferenceRelevance
" The assay has been applied successfully in a pharmacokinetic study of cinepazide maleate after a single intravenous at three doses in rat."( High performance liquid chromatographic method for the determination of cinepazide maleate and its application to a pharmacokinetic study in rats.
Hai, W; Jia, Y; Li, Y; Liu, M; Lu, C; Song, Y; Sun, Y; Wang, H; Wang, S; Wen, A; Zhao, J; Zhu, X, 2014
)
0.87

Compound-Compound Interactions

ExcerptReferenceRelevance
" Patients in the observation group underwent conventional treatment combined with neuroprotective therapeutic strategies."( Neuroprotective strategies for patients with acute myocardial infarction combined with hypoxic ischemic encephalopathy in the ICU.
Chao, Y; Geng, X; Hu, W,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" And cinepazide maleate injection can improve the bioavailability of cinepazide maleate greatly, and has a dose-dependence profile in rats."( High performance liquid chromatographic method for the determination of cinepazide maleate and its application to a pharmacokinetic study in rats.
Hai, W; Jia, Y; Li, Y; Liu, M; Lu, C; Song, Y; Sun, Y; Wang, H; Wang, S; Wen, A; Zhao, J; Zhu, X, 2014
)
1.15
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The injection is administered intravenously,with most patients receiving a dosage of 15-20 mL per dose for between 1 and 14 days."( [Analysis of clinical use of shuxuening injection in treatment of cerebral infarction based on real world].
Luo, YH; Wang, YY; Xie, YM; Yang, W; You, L; Zhuang, Y, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
olefinic compoundAny organic molecular entity that contains at least one C=C bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (48.39)18.7374
1990's3 (9.68)18.2507
2000's0 (0.00)29.6817
2010's8 (25.81)24.3611
2020's5 (16.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.38 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index20.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (9.09%)5.53%
Reviews1 (3.03%)6.00%
Case Studies8 (24.24%)4.05%
Observational0 (0.00%)0.25%
Other21 (63.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Cinepazide Maleate Injection in the Treatment of Acute Ischemic Stroke A Blind, Multicenter, Placebo-controlled Clinical Confirmatory Study. [NCT04951232]1,000 participants (Actual)Interventional2016-07-04Completed
A Random, Double-blind, Placebo- Controlled and Dose-finding, Multi-center, Phase II Clinical Trial of Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction [NCT01851759]Phase 2288 participants (Anticipated)Interventional2013-10-31Not yet recruiting
Efficacy and Safety of Mildronate for Acute Ischemic Stroke: a Randomized, Double-blind, Active-controlled Phase II Multicenter Trial [NCT01831011]Phase 2227 participants (Actual)Interventional2008-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]